ABL1 and acute myeloid leukemia: With the exception of lesion-level modeling, all recommendations in the above sections can be applied to hematologic malignancies, where total target tumor size is replaced by the appropriate continuous tumor burden metric for that particular malignancy: M-protein levels in secretory multiple myeloma patients, percent blasts in AML, and BCRABL/ABL ratio in CML.